Pyxis Oncology, Inc.
321 Harrison Avenue
Boston, MA 02118
April 1, 2024
Via EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549-3720
Attention: |
Tim Buchmiller |
Re: |
|
Pyxis Oncology, Inc. Registration Statement on Form S-3, as amended File No. 333-278282 |
|
|
|
|
|
|
|
Acceleration Request |
|
|
|
Requested Date: April 3, 2024 |
|
|
|
Requested Time: 4:00 P.M., Eastern Time |
|
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Pyxis Oncology, Inc. (the “Company”) hereby requests that the effective date of the above-referenced Registration Statement on Form S-3, as amended (the “Registration Statement”), be accelerated so that the Registration Statement will become effective at 4:00 P.M., Eastern Time, on April 3, 2024, or as soon thereafter as practicable or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the U.S. Securities and Exchange Commission.
Please contact Kostian Ciko of Sidley Austin LLP at (212) 839-5450 with any questions regarding the foregoing and to confirm the effectiveness of the Registration Statement.
Very truly yours, |
|
|
/s/ Lara Sullivan |
Lara Sullivan |
Chief Executive Officer |
Pyxis Oncology, Inc. |
cc: |
Pam Connealy, Pyxis Oncology, Inc. |